IQM to Deliver Its First Quantum Computer in South America to Brazil’s Eldorado Research Institute
17.9.2026 09:43:00 CEST | Business Wire | Press Release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced a purchase agreement with the Eldorado Research Institute to deploy its first quantum computer in South America, marking IQM's entry into the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917582765/en/
IQM to deliver its first quantum computer in South America to Brazil’s Eldorado Research Institute
The IQM Spark quantum computer will be installed at Eldorado's Campinas headquarters, about 100km northwest of São Paulo, in the first quarter of 2027, giving researchers, engineers, universities and industry partners direct access to quantum computers.
The agreement also includes remote access to IQM's 54-qubit cloud-based system in Europe, allowing Brazilian teams to develop applications on hardware they own and then move to larger-scale quantum workloads when a problem requires it.
“Brazil has the talent, the research base and the ambition to build a real quantum ecosystem. What's been missing is direct access to real quantum computers. Eldorado owning this system means Brazilian researchers, engineers and industry partners can start building real capability today, not waiting years to catch up,” said Jan Goetz, CEO and Co-founder of IQM Quantum Computers. “This is our first step into South America, and we're approaching it the same way we have everywhere else: with a partner who wants to grow with their own infrastructure and shape how it's used.”
“Quantum computing has the potential to transform how we address some of the most complex technological and industrial challenges. By bringing this infrastructure to Eldorado, combined with access to more advanced quantum computing capabilities, we are not only investing in technology, we are investing in people, knowledge and an ecosystem that will prepare Brazil to actively participate in the quantum future,” said José Bertuzzo, Superintendent of the Eldorado Research Institute.
Eldorado's Campinas headquarters sits alongside the Unicamp campus in Brazil's largest technology cluster, giving the system immediate reach into a network of universities, startups and industry partners across sectors including automotive, energy, oil and gas, fintech, agribusiness and healthcare.
The quantum computer will enable Eldorado and its partners to explore quantum algorithms, build expertise in quantum hardware and software, and investigate hybrid architectures combining high-performance computing, quantum computing and artificial intelligence. The deployment is part of Eldorado’s strategy to expand its activities in emerging technologies and to build capabilities relevant to the next generation of computing.
The agreement follows a period of expansion for IQM. In August, the company reported an order backlog of EUR 102 million, with 26 full-stack systems sold and 17 delivered globally, including its first system in the United States.
About IQM Quantum Computers
IQM Quantum Computers (Nasdaq: IQMX) is a global leader in superconducting quantum computers, delivering full-stack quantum systems and cloud platform access to enterprises, research institutions, universities, high-performance computing centers, and national laboratories worldwide. IQM's open, modular architecture allows customers to own, operate, and integrate quantum systems directly into their own infrastructure, building lasting technical capability rather than relying solely on remote access. Founded in 2018, IQM is headquartered in Espoo, Finland, with major operations in Munich, Germany, and has sold more quantum systems than any other manufacturer to date. IQM employs over 450 people and operates across Europe, Asia, and North America. IQM is the first publicly listed European quantum company on Nasdaq Stock Market.
About Eldorado Research Institute
A leading research, development and innovation institution in Brazil, Eldorado has more than 27 years of experience developing innovative solutions for national and international companies across the information and communication technology, automotive, agribusiness, energy, oil and gas, fintech, and healthcare sectors.
With operations in Campinas, Manaus, Porto Alegre and Brasília, Eldorado has world-class laboratories and plays a leading role in open innovation and in leveraging funding mechanisms and incentives for R&D projects. The Institute brings together professionals with expertise in microelectronics, hardware and software solution development, testing and certification, and technology training. Eldorado invests extensively in knowledge creation and the continuous development of its teams to deliver differentiated results to its clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260917582765/en/
Contacts
Media contacts
IQM — Email: press@iqm.tech · Mobile: +358 (0) 50 479 0845
Eldorado — comunicacao@eldorado.org.br · Mobile + 55 11 996621192 or + 55 19
37573000
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom